Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium chloride + phenol (aqueous phenol) is a neurolytic solution used primarily for the management of severe spasticity and chronic pain. Phenol acts as a chemical neurolytic agent that induces non-selective protein denaturation and subsequent Wallerian degeneration of nerve fibers when injected in close proximity to nerves or motor points. This process leads to a long-lasting but typically reversible interruption of nerve conduction, effectively reducing muscle tone in conditions such as cerebral palsy, stroke, or spinal cord injury. The saline component serves as a sterile vehicle for the phenol, which is typically used at concentrations ranging from 3% to 7% for neurolytic procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium chloride + phenol.